Please login to the form below

Not currently logged in
Email:
Password:

Brintellix

This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.

Lundbeck sways NICE with new Brintellix data

Lundbeck sways NICE with new Brintellix data

NICE has recommended Lundbeck's Brintellix for adults with major depressive order in final draft guidance. ... The submission included data from the REVIVE trial which compared Brintellix with Servier's Valdoxan (agomelatine).

Latest news

  • Lundbeck to cut 1,000 jobs in major restructure Lundbeck to cut 1,000 jobs in major restructure

    Lundbeck's focus will now turn more to its newer drugs such as Brintellix (vortioxetine), Northera (droxidopa), Onfi (clobazam) and Abilify Maintena (aripriprazole) which saw a 190% growth in sales.

  • US filing aims to elevate Brintellix above its competition US filing aims to elevate Brintellix above its competition

    US filing aims to elevate Brintellix above its competition. Drug looking for an edge in the highly competitive major depressive disorder market. ... Lundbeck and Takeda have filed for US approval of new labelling for their antidepressant Brintellix that

  • Lundbeck and Otsuka's Rexulti set for August launch in US Lundbeck and Otsuka's Rexulti set for August launch in US

    Meanwhile, Rexulti is one of string of new drugs at Lundbeck - along with the likes of long-acting aripiprazole depot Abilify Maintena (also partnered with Otsuka) and new antidepressant Brintellix (vortioxetine) -

  • Schultz takes Lundbeck helm after leaving Novo Nordisk Schultz takes Lundbeck helm after leaving Novo Nordisk

    120m kroner and antidepressant Brintellix (vortioxetine) adding another 98m kroner, up from 8m kroner a year ago. ... Brintellix has now been launched in 20 countries and while uptake is "still limited outside the Nordic countries and the Netherlands,"

  • Brintellix first antidepressant with cognition claim in Europe Brintellix first antidepressant with cognition claim in Europe

    Brintellix first antidepressant with cognition claim in Europe. Trial found it performed better than Lilly’ s rival Cymbalta. ... The Danish company also has a long-acting version of schizophrenia drug Abilify (aripiprazole) and alcohol addiction

More from news
Approximately 8 fully matching, plus 18 partially matching documents found.

Latest appointments

  • Bayer’s Barbara Jaszewski joins Lundbeck Bayer’s Barbara Jaszewski joins Lundbeck

    In addition, Lundbeck also has Brintellix (vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify (aripiprazole) is also due to launch during 2013.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Agnitio

Agnitio is a leading supplier of state-of-the-art multichannel communication. Specialists in digital communication tools for the global life sciences industry,...

Latest intelligence

Harnessing complexity
Companion diagnostics in oncology...
"Not Another Boring Survey?"
Winning over HCPs… How to Increase Participant Engagement in Healthcare Market Research...
What pharma needs to know about genomic data in 2016
Consultant David Cooney from Blue Latitude Health talks us through what this progress in genomics means for pharma in 2016....

Infographics